BioPharma Dive reports that a patient who received Bristol Myers’ zola-cel, an autoimmune CAR-T therapy, died 44 days after treatment. In a separate move, Gilead has acquired a company for nearly $1.3 billion to challenge Johnson & Johnson’s new psoriasis drug.
These developments raise concerns for pharma executives about the safety profile of advanced therapies and the competitive pressures in immunology. The death linked to zola-cel may prompt closer regulatory scrutiny, while Gilead’s acquisition signals ongoing competition in the autoimmune market.
